OBS-1

OBS-1 is an investigational drug candidate currently in the discovery and preclinical stages of development by insitro for the treatment of obesity. The program leverages insitro's proprietary AI-enabled platform, which integrates high-throughput biology and machine learning to identify novel therapeutic targets within complex metabolic pathways. While the specific molecular target and therapeutic modality of OBS-1 have not been publicly disclosed, insitro's obesity research has focused on brown adipose tissue (BAT) biology and peripheral mechanisms of weight loss that are distinct from centrally acting appetite suppressants. The asset represents part of the company's broader effort to apply computational modeling to endocrine and metabolic diseases.